1-pentyl-4-methylpiperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-pentyl-4-methylpiperidine
• 英文别名: 4-methyl-1-pentyl-piperidine；4-Methyl-1-pentyl-piperidin；Piperidine, 4-methyl-1-pentyl；4-methyl-1-pentylpiperidine
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: WJUZBGRSFLQLCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-甲基戊二酸 在 1,4-二氧六环 、 copper oxide-chromium oxide 、 硫酸 作用下， 200.0~250.0 ℃ 、39.22 MPa 条件下， 生成 1-pentyl-4-methylpiperidine
  参考文献：
  名称：

  Paden; Adkins, Journal of the American Chemical Society, 1936, vol. 58, p. 2493

  摘要：

  DOI：

文献信息

• Photometric Characterization of the Reductive Amination Scope of the Imine Reductases from<i>Streptomyces tsukubaensis</i>and<i>Streptomyces ipomoeae</i>
  作者：Philipp Matzel、Lukas Krautschick、Matthias Höhne

  DOI：10.1002/cbic.201700257

  日期：2017.10.18

  reductive amination catalyzed by two promising imine reductases is established in a rapid photometric NADPH assay. Substrates ranging from aldehydes to ketones and from primary to secondary amines are accepted, thus giving access to various secondary and tertiary amine products.

  两种酶663种组合：在快速光度NADPH分析中确定了由两种有前途的亚胺还原酶催化的还原胺化中的底物范围。可以接受从醛到酮以及从伯胺到仲胺的各种底物，因此可以使用各种仲胺和叔胺产品。
• 2-AMINOBENZAMIDE DERIVATIVE
  申请人：Kuramochi Takahiro

  公开号：US20090233900A1

  公开（公告）日：2009-09-17

  To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.

  本发明提供了一种基于对辣椒素受体VR1激活的抑制作用的新型优良药剂，用于治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等疾病。本发明通过确认一种苯甲酰胺衍生物，其特征在于其苯环上的单环在酰胺基氮原子上被紧缩，其低烷基氨基或邻位于酰胺基的环基取代的氨基具有对VR1激活的强抑制作用和优良的药理作用，从而发现它可以成为治疗或预防伤害性疼痛、神经病理性疼痛、癌症疼痛、头痛、膀胱功能障碍等VR1相关疾病的优良药剂。
• Katritzky, Alan R.; Parris, Roslyn L.; Ignatchenko, Elena S., Advanced Synthesis and Catalysis, 1996, vol. 338, # 3, p. 220 - 230
  作者：Katritzky, Alan R.、Parris, Roslyn L.、Ignatchenko, Elena S.、Balasubramanian, Marudai、Barcock, Richard A.、Siskin, Michael

  DOI：——

  日期：——
• 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER
  申请人：Astellas Pharma Inc.

  公开号：EP1955697B1

  公开（公告）日：2012-05-02
• 5-HT4 RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0604494B1

  公开（公告）日：1999-07-28